Tao Song1, Long Chen1, Haibo Zhang1, Yanwei Lu1, Kun Yu2, Wenming Zhan1, Min Fang1. 1. Department of Radiation Oncology, Cancer Center of Zhejiang Provincial People's Hospital, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. 2. Department of Head & Neck Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Abstract
BACKGROUND: The aim of this retrospective study was to evaluate multimodal treatments consisting of surgery, radiotherapy (RT) and chemotherapy (CT) in metastatic anaplastic thyroid carcinoma (ATC) patients using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: Patients with a histopathologic diagnosis of ATC between 1998 and 2015 were included. The endpoint of this study was overall survival (OS). The prognostic significance in terms of OS was analyzed by univariate and multivariate analyses. RESULTS: A total of 433 metastatic ATC patients were identified. The median OS was two months, with a 1-year OS rate of 6.9%. In the multivariate analysis, the factors significantly correlated with OS were age [<68 vs. ≥68 years old, P=0.032, hazard ratio (HR) =1.252], tumor size (<7 vs. ≥7 cm, P=0.004, HR =1.418; <7 cm vs. unknown, P=0.005, HR =1.424), surgery at the primary site (none/unknown vs. less than thyroidectomy, P<0.001, HR =0.623; none/unknown vs. thyroidectomy, P=0.001, HR =0.616), use of RT (P<0.001, HR =0.562) and use of CT (P<0.001, HR =0.621). In the subgroup analysis, the combination of thyroidectomy, RT and CT demonstrated the best OS outcome when compared with other therapeutic modalities. CONCLUSIONS: Surgery, RT and CT were all strong prognostic factors for improved OS in metastatic ATC patients. In addition, treatment approaches consisting of thyroidectomy were beneficial compared with nonsurgical treatment. However, given the limited benefit of only a few months in the clinic, we suggest that thyroidectomy in combination with RT and CT should be delivered in selected patients with caution for better management of metastatic ATC. 2020 Gland Surgery. All rights reserved.
BACKGROUND: The aim of this retrospective study was to evaluate multimodal treatments consisting of surgery, radiotherapy (RT) and chemotherapy (CT) in metastatic anaplastic thyroid carcinoma (ATC) patients using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: Patients with a histopathologic diagnosis of ATC between 1998 and 2015 were included. The endpoint of this study was overall survival (OS). The prognostic significance in terms of OS was analyzed by univariate and multivariate analyses. RESULTS: A total of 433 metastatic ATC patients were identified. The median OS was two months, with a 1-year OS rate of 6.9%. In the multivariate analysis, the factors significantly correlated with OS were age [<68 vs. ≥68 years old, P=0.032, hazard ratio (HR) =1.252], tumor size (<7 vs. ≥7 cm, P=0.004, HR =1.418; <7 cm vs. unknown, P=0.005, HR =1.424), surgery at the primary site (none/unknown vs. less than thyroidectomy, P<0.001, HR =0.623; none/unknown vs. thyroidectomy, P=0.001, HR =0.616), use of RT (P<0.001, HR =0.562) and use of CT (P<0.001, HR =0.621). In the subgroup analysis, the combination of thyroidectomy, RT and CT demonstrated the best OS outcome when compared with other therapeutic modalities. CONCLUSIONS: Surgery, RT and CT were all strong prognostic factors for improved OS in metastatic ATC patients. In addition, treatment approaches consisting of thyroidectomy were beneficial compared with nonsurgical treatment. However, given the limited benefit of only a few months in the clinic, we suggest that thyroidectomy in combination with RT and CT should be delivered in selected patients with caution for better management of metastatic ATC. 2020 Gland Surgery. All rights reserved.
Authors: Robert L Foote; Julian R Molina; Jan L Kasperbauer; Ricardo V Lloyd; Bryan McIver; John C Morris; Clive S Grant; Geoffrey B Thompson; Melanie L Richards; Ian D Hay; Robert C Smallridge; Keith C Bible Journal: Thyroid Date: 2010-12-16 Impact factor: 6.568
Authors: Annemarie T Swaak-Kragten; Johannes H W de Wilt; Paul I M Schmitz; Marijke Bontenbal; Peter C Levendag Journal: Radiother Oncol Date: 2009-03-26 Impact factor: 6.280
Authors: Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn Journal: Cancer Date: 2016-12-27 Impact factor: 6.860
Authors: Ashish V Chintakuntlawar; Robert L Foote; Jan L Kasperbauer; Keith C Bible Journal: Endocrinol Metab Clin North Am Date: 2019-03 Impact factor: 4.741
Authors: Vera Tiedje; Martin Stuschke; Frank Weber; Henning Dralle; Laura Moss; Dagmar Führer Journal: Endocr Relat Cancer Date: 2018-01-02 Impact factor: 5.678
Authors: Renaud De Crevoisier; Eric Baudin; Anne Bachelot; Sophie Leboulleux; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens Journal: Langenbecks Arch Surg Date: 2013-03-03 Impact factor: 3.445